The KIAA0586 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from human A-549 lung adenocarcinoma cells, engineered to disrupt the KIAA0586 (TAB2) gene. This gene-edited model employs CRISPR/Cas9-mediated targeted disruption, generating a heterogeneous population of cells with loss-of-function mutations. The polyclonal nature avoids clonal selection bias, providing a genetically diverse tool for studying TAB2 function in innate immune and inflammatory signaling.
The A-549 parental line originates from lung adenocarcinoma of a 58-year-old male and harbors a KRAS G12S activating mutation. These epithelial cells serve as a well-established model for non-small cell lung cancer (NSCLC), recapitulating key features of tumor biology including constitutive activation of survival and inflammatory pathways. This genetic background makes A-549 an ideal host for dissecting the role of adaptor proteins in oncogenic signaling.
TAB2 acts as an adaptor linking activated IL-1R, TNFR1, and TLR4 to the TAK1 kinase complex. Upon ligand stimulation (IL-1??, TNF??, LPS), TAB2 recognizes polyubiquitinated TRAF6 or RIP1, facilitating TAK1 autophosphorylation and activation. This leads to IKK-mediated phosphorylation of I??B??, releasing NF-??B (p65/p50) for nuclear translocation and transcription of targets like IL-6 and IL-8. Concurrently, TAK1 phosphorylates MKK4/7, activating JNK and AP-1. TAB2 partners with TAB1 and TAB3 to stabilize the TAK1 complex, ensuring robust signaling downstream of MyD88/TRIF.
In A-549 cells, where oncogenic KRAS drives tumorigenesis, TAB2-mediated inflammatory signaling may promote a supportive tumor microenvironment and resistance to apoptosis. Disruption of TAB2 allows researchers to decouple IL-1/TNF/TLR-driven NF-??B and JNK activation from KRAS effector pathways, providing insight into the contribution of inflammatory adaptors to lung adenocarcinoma progression and drug response. This model is valuable for investigating how inflammatory signals influence chemosensitivity to agents like cisplatin and paclitaxel.
These polyclonal knockout cells are suitable for analyzing IL-1/TNF/TLR signaling by western blot (phospho-p65, phospho-JNK), NF-??B reporter assays, and ELISA for IL-6 and IL-8. Co-immunoprecipitation can assess TAK1 complex integrity, while RT-qPCR profiles NF-??B targets. Functional assays include annexin V apoptosis and wound healing migration. Drug sensitivity testing with cisplatin or paclitaxel explores chemoresistance mechanisms. For further details, contact Ascent Research.
